The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU) (FOLFIRINOX) and nab-paclitaxel/gemcitabine in patients with pancreatic cancer.
The secondary objectives of this trial are to determine preliminary clinical efficacy based on response rates, overall survival and progression free survival compared with historic control, and surgical conversion rate as defined as percent of locally advanced (unresectable) patients achieving resectability within 6 months of treatment initiation. Also, to identify vaccine immunogenicity by measuring acquired, T cell-mediated immune activating events post-vaccination and to correlate clinical response with acquired immune responses.

开始日期2015-08-01

申办/合作机构

Baylor Research Institute

NCT00796770 / Completed临床1期IIT

Vaccination of HIV-1 Infected Patients With Ex-vivo Generated Interferon-α Dendritic Cells Loaded With HIV-1 Lipopeptides and Activated With Lipopolysaccharide in Addition to Antiretroviral Treatment: Exploratory Phase I Study-(DALIA Trial)

The purpose of this study is to determine whether the administration of a dendritic cell vaccine is a safe and effective treatment for HIV-1 patients.

开始日期2008-11-01

申办/合作机构

Baylor Research Institute

[+1]

NCT00510497 / Completed临床1/2期IIT

Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells

This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus. It also aims to explore the virologic efficacy of the vaccine as determined by a decrease in the viral load 12 weeks after analytic treatment interruption.

开始日期2007-07-01

申办/合作机构

University of Pittsburgh

[+1]

100 项与 Dendritic Cell Vaccine(Baylor Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Dendritic Cell Vaccine(Baylor Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Dendritic Cell Vaccine(Baylor Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Dendritic Cell Vaccine(Baylor Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性黑色素瘤IV期	临床2期	美国	Baylor Research Institute	2008-06-01
胰腺癌	临床1期	美国	Baylor Research Institute	2015-08-01
获得性免疫缺陷综合征	临床1期	美国	Baylor Research Institute	2008-11-30
机会致病菌感染	临床1期	美国	Baylor Research Institute	2008-11-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00510497 (CTgov)	临床1/2期	HIV感染	11	Autologous HIV-1 ApB DC Vaccine	淵糧鹹範範觸鏇繭廠繭(繭衊艱鹽夢壓夢衊積鏇) = 蓋獵繭鏇壓遞憲鹽繭遞衊築艱築憲遞繭淵積簾 (糧觸鏇構範艱餘範憲構, 淵獵艱鑰鏇齋餘壓願艱 ~ 淵選願積餘衊窪構選鹹) 更多	-	2016-04-04